Mylan Laboratories Limited Emtricitabine Export Data — India (DGFT 2022–2026)

Name: Mylan Laboratories Limited Emtricitabine Export Records India — #1 Exporter, 265 Shipments, $13.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Emtricitabine

India Pharmaceutical Trade Intelligence

$119.4M141 Suppliers117 CountriesHS 30049099

ExportsIndia → SOUTH AFRICA26.2%India → UNITED STATES13.1%

ImportsUNITED STATES → India$942.1K CANADA → India$171.0K

#1 Supplier: MYLAN LABORATORIES

Mylan Laboratories Limited — Emtricitabine Exporter #1 | $13.3M Trade Value | TransData Nexus | TransData Nexus

Mylan Laboratories Limited — Emtricitabine Exporter Profile

Indian Pharmaceutical Exporter · #1 for Emtricitabine · $13.3M export value · DGFT Verified

Mylan Laboratories Limited is the #1 Indian exporter of Emtricitabine with $13.3M in export value and 265 verified shipments. Mylan Laboratories Limited holds a 11.1% market share in Emtricitabine exports across 53 countries. The company exports 91 pharmaceutical products worth $634.8M across 26 therapeutic categories.

Mylan Laboratories Limited — Emtricitabine Export Profile: Buyers & Destinations

Mylan Laboratories Limited Emtricitabine export treemap — buyers and destination countries | TransData Nexus

Where Does Mylan Laboratories Limited Export Emtricitabine?

Country	Value	Shipments	Share
SOUTH AFRICA	$1.8M	39	22.4%
MALAYSIA	$683.4K	21	8.6%
VIETNAM, DEMOCRATIC REP. OF	$632.0K	13	8.0%
UNITED STATES	$545.2K	12	6.9%

Who Are the Top Buyers of Emtricitabine from Mylan Laboratories Limited?

Buyer	Country	Value	Orders
CENTRAL PHARMACEUTICAL CPC1. JSC	VIETNAM, DEMOCRATIC REP. OF	$594.2K	12
VIATRIS HEALTHCARE (PTY) LTD,	SOUTH AFRICA	$491.9K	12
PAHANG PHARMACY SDN BHD,	MALAYSIA	$350.0K	7
PAHANG PHARMACY SDN BHD	MALAYSIA	$333.4K	14
MYLAN PHARMACEUTICALS INC	UNITED STATES	$315.9K	7
VIATRIS HEALTHCARE (PTY) LTD,'	SOUTH AFRICA	$304.7K	7
MINISTERIO DE SALUD DE LA NACION	ARGENTINA	$300.0K	6
USAID MALAWI	MOZAMBIQUE	$284.8K	6
DSV HEALTHCARE,	SOUTH AFRICA	$250.0K	5
CENTRAL PHARMACEUTICAL CPC1.JSC	VIETNAM, DEMOCRATIC REP. OF	$223.3K	6

Mylan Laboratories Limited supplies Emtricitabine to 103 buyers globally. The largest buyer is CENTRAL PHARMACEUTICAL CPC1. JSC (VIETNAM, DEMOCRATIC REP. OF), followed by VIATRIS HEALTHCARE (PTY) LTD, (SOUTH AFRICA) and PAHANG PHARMACY SDN BHD, (MALAYSIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Emtricitabine Formulations Does Mylan Laboratories Limited Export?

Product Description / Formulation	Value	Shipments
EMTRICITABINE AND TENOFOVIR DISOPROXIL F	$150.0K	3
(RICOVIR) TENOFOVIR DISOPROXIL FUMARATE300 MG+ EMTRICITABINE 200 MG TAB(30S)(PACKS 30S BOTTLE)(58912 PACKS X 30S=1NOS	$150.0K	3
ERESTZ 30'S(EMTRICITABINE200MG+RILPIVIRINE25MG+TENOFOVIRDISOPROXILFUMARATE300MGTAB'S) (31245PACKS X 30'S = 937350 NOS)NOS	$150.0K	3
TENOFOVIR DISOPROXIL FUMARATE 300MG+EMTRICITABINE 200MG TABLETS (30'S) (57792 PACKX30 NOS)NOS	$150.0K	3
TENOFOVIR DISOPROXIL FUMARATE 300 MG+EMTRICITABINE 200 MG TAB(30'S) (322731 PACKS X 30'S = 9681930 NOS)NOS	$150.0K	3
TENOFOVIR DISOPROXIL FUMARATE 300MG+ EMTRICITABINE 200MG TABLETS (30'S)(46866 PACKS X 30 NOS)NOS	$150.0K	3
TENOFOVIR DISOPROXIL FUMARATE 300MG + EMTRICITABINE 200MG TABLETS (30'S)(58588 PACKS X 30 NOS)NOS	$150.0K	3
TENOFOVIR DISOPROXIL FUMARATE 300MG + EMTRICITABINE 200MG TABLETS (30'S) (58869PACKS X30 NOS)NOS	$150.0K	3
TENOFOVIR DISOPROXIL FUMARATE 300 MG+EMTRICITABINE 200 MG TAB(30'S) (155840 PACKS X 30'S = 4675200 NOS )NOS	$150.0K	3
TENOFOVIR DISOPROXIL FUMARATE 300MG+EMTRICITABINE 200MG TAB(30'S) - NO CARTON (181,167.000 PACKS : 30'S BOTTLE)	$150.0K	3

Mylan Laboratories Limited exports 174 distinct Emtricitabine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is EMTRICITABINE AND TENOFOVIR DISOPROXIL F with 3 shipments worth $150.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.

How Does Mylan Laboratories Limited Compare to Nearest Emtricitabine Exporters?

Exporters ranked immediately above and below #1 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
2	MACLEODS PHARMACEUTICALS LTD	$14.0M	280	34	$50.0K
1	MYLAN LABORATORIES LIMITED ★	$13.3M	265	53	$50.0K
3	AUROBINDO PHARMA LTD	$5.9M	118	9	$50.0K
7	MACLEODS PHARMACEUTICALS LIMITED	$4.2M	107	19	$38.8K

Mylan Laboratories Limited ranks #1 among 141 Indian Emtricitabine exporters. Average shipment value of $50.0K compared to the market average of $363.2K. The closest competitors by value are MACLEODS PHARMACEUTICALS LTD and AUROBINDO PHARMA LTD.

Which Indian Ports Ship Emtricitabine Exports?

Port	Shipments	% Share
SAHAR AIR CARGO ACC (INBOM4)	524	23.9%
SAHAR AIR	469	21.4%
Bombay Air	166	7.6%
DELHI AIR	153	7.0%
DELHI AIR CARGO ACC (INDEL4)	141	6.4%
NHAVA SHEVA SEA (INNSA1)	60	2.7%
Bombay Air Cargo	55	2.5%
HYDERABAD ACC (INHYD4)	54	2.5%

Geopolitical & Trade Policy Impact on Mylan Laboratories Limited's Emtricitabine Exports

Mylan's export operations are influenced by a complex geopolitical landscape. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. Major shipping lines have implemented 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, directly impacting the cost structure for Indian pharmaceutical exporters like Mylan. Additionally, diversions around the Cape of Good Hope have further elongated delivery schedules, posing challenges to time-sensitive pharmaceutical shipments.

In the United States, the imposition of tariffs on pharmaceutical imports has prompted Indian companies to reassess their market strategies. While generics have largely remained exempt, the potential for future tariff expansions necessitates vigilance. Mylan, along with other Indian exporters, is exploring market diversification to mitigate reliance on the U.S. market. The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, offers a strategic avenue for expansion. The FTA eliminates tariffs on approximately 97% of EU tariff lines, including pharmaceuticals, thereby enhancing market access for Indian exporters. This agreement is expected to significantly boost India's pharmaceutical exports to Europe, providing a counterbalance to uncertainties in the U.S. market.

Mylan Laboratories Limited — Regulatory Compliance & Quality Standards

Compliance with international regulatory standards remains paramount for Mylan. The FDA's warning letter and import alert in December 2024 concerning the Indore facility underscore the critical importance of stringent quality control measures. The cited violations, including subpar quality control and improper management of manufacturing defects, have necessitated comprehensive corrective actions. Mylan's proactive response aims to restore compliance and reinforce its commitment to quality assurance.

The evolving regulatory environment, particularly in the European Union, further emphasizes the need for adherence to Good Manufacturing Practices (GMP). The EU's Falsified Medicines Directive mandates rigorous compliance to ensure product integrity and patient safety. For Mylan, aligning with these standards is essential to maintain and expand its foothold in the European market.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Emtricitabine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Mylan Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 265 individual customs records matching Mylan Laboratories Limited exporting Emtricitabine, covering 174 formulations to 56 countries via 103 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 117+ countries, 493+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Emtricitabine

Emtricitabine

Mylan Laboratories Limited — Emtricitabine Exporter Profile

Mylan Laboratories Limited — Emtricitabine Export Profile: Buyers & Destinations

Where Does Mylan Laboratories Limited Export Emtricitabine?

Who Are the Top Buyers of Emtricitabine from Mylan Laboratories Limited?

What Is India's Total Emtricitabine Export Value and How Much Does Mylan Laboratories Limited Contribute?

What Is the Average Shipment Value for Mylan Laboratories Limited's Emtricitabine Exports?

How Does Mylan Laboratories Limited Compare to Other Indian Emtricitabine Exporters?

What Emtricitabine Formulations Does Mylan Laboratories Limited Export?

Regulatory Requirements: Exporting Emtricitabine to Key Markets

South Africa — SAHPRA

How Does Mylan Laboratories Limited Compare to Nearest Emtricitabine Exporters?

Which Indian Ports Ship Emtricitabine Exports?

What Other Antiviral & HIV Medications Products Does Mylan Laboratories Limited Export?

Geopolitical & Trade Policy Impact on Mylan Laboratories Limited's Emtricitabine Exports

Mylan Laboratories Limited — Regulatory Compliance & Quality Standards

About Mylan Laboratories Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Emtricitabine Export Data from Mylan Laboratories Limited

Emtricitabine Stats

Company Overview

Top Products by Mylan Laboratories Limited

Related Analysis

Need Detailed Export Data?

Data Source